Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 1999
[Serum levels of soluble intercellular adhesion molecule 1 in malignant lymphoproliferative disorders].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li D, Li G, Cui W
Аннотация
OBJECTIVE: To investigate the correlation of serum levels of soluble intercellular adhesion molecule 1 (sICAM-1) with clinical situation and treatment outcome in lymphoproliferative disorders.
METHODS: Serum sICAM-1 levels were measured by immunoenzymatic assay.
RESULTS: Pre-treatment serum sICAM-1 levels were above normal in 41% (9/22) of multiple myeloma (MM), 53% (17/32) of non-Hodgkin's lymphoma (NHL) and 63% (12/19) of acute lymphocytic leukemia (ALL) patients. Serum sICAM-1 levels in MM were positively correlated with Bataille stages, but were not related to Durie stage. Meanwhile, sICAM-1 levels in NHL were associated with the category of pathology, Ann Arbor stage and B symptom, but were not related to serum LDH levels. sICAM-1 levels were significantly higher in ALL patients complicated with central nervous system leukemia (CNSL) than in those without CNSL. Patients with elevated serum sICAM-1 levels had poorer treatment outcomes. Serum sICAM-1 levels were returned to normal at remission.
CONCLUSION: Measurement of serum sICAM-1 levels in lymphoproliferative disorders patients is helpful for judging the clinical status and treatment outcome.
METHODS: Serum sICAM-1 levels were measured by immunoenzymatic assay.
RESULTS: Pre-treatment serum sICAM-1 levels were above normal in 41% (9/22) of multiple myeloma (MM), 53% (17/32) of non-Hodgkin's lymphoma (NHL) and 63% (12/19) of acute lymphocytic leukemia (ALL) patients. Serum sICAM-1 levels in MM were positively correlated with Bataille stages, but were not related to Durie stage. Meanwhile, sICAM-1 levels in NHL were associated with the category of pathology, Ann Arbor stage and B symptom, but were not related to serum LDH levels. sICAM-1 levels were significantly higher in ALL patients complicated with central nervous system leukemia (CNSL) than in those without CNSL. Patients with elevated serum sICAM-1 levels had poorer treatment outcomes. Serum sICAM-1 levels were returned to normal at remission.
CONCLUSION: Measurement of serum sICAM-1 levels in lymphoproliferative disorders patients is helpful for judging the clinical status and treatment outcome.